logo
'Beware' Mousse-Based Sunscreen, FDA Warns

'Beware' Mousse-Based Sunscreen, FDA Warns

Newsweek6 hours ago
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
While some sunscreens may look more appealing than others, the jury is now out on whether certain types do what they say on the bottle.
The Food and Drug Administration (FDA) has issued a warning to "beware" sunscreen products that come in mousse form because they might not be effective.
The federal agency has sent warning letters to five companies marketing sunscreen products in mousse-style—including brands Supergoop!, Vacation Inc., Kalani Sunwear, Botao Baby and Tizo Skin—and citing efficacy concerns, regulatory violations and packaging risks.
Some companies are already pulling products from their U.S. sites, such as Kalani Sunwear.
Woman applying sunscreen on man's face outdoors.
Woman applying sunscreen on man's face outdoors.
JordiThe FDA's letter to Supergoop!, for example, reads in part: "This letter is to advise you that on May 2nd, 2025 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including your website, http://supergoop.com/, where your 'Supergoop! PLAY SPF 50 BODY MOUSSE' drug product is available for purchase in the United States without a prescription."
It said that based on their labeling—e.g. "Broad Spectrum Sunscreen SPF 50" and "Helps prevent sunburn..."—it is intended for use as an over-the-counter (OTC) sunscreen drug product, but no FDA-approved relevant application is in effect for this.
On X, the FDA also warned: "Some mousse sunscreen products resemble whipped cream containers and may put consumers at risk if ingested."
Beware of sunscreen products in mousse form because they might not be effective. The FDA issued five warning letters to companies marketing sunscreen products in mousse form: https://t.co/z0kHZqULna pic.twitter.com/xZPtgqWQqE — FDA Drug Information (@FDA_Drug_Info) August 12, 2025
In light of this, Newsweek spoke to dermatologist professor Adam Friedman of the George Washington University about what the FDA warning means for Americans' sunscreen routines and how to choose safe and effective protection.
"Sunscreens are OTC drugs, which distinguishes them from a moisturizer or a cosmeceutical. It means the regulation, the expectation in terms of efficacy, how well it works and safety is going to be different," Friedman explained.
"But also what it relates to is not just the active ingredient, but the formulation—and that's where the whole mess comes in.
"As of right now, under the 'monograph'—the umbrella of what is considered a sunscreen—oils, creams, lotions, gels, butters, pastes, ointments, powders, sprays and sticks fall under the category. Mousses and foams do not."
Efficacy and safety are then a separate issue.
"A mousse or a foam are aerated, and therefore how they interface with the skin when you rub them on may be very different from a cream or a spray or a stick," said Friedman.
"We don't know if, based on that formulation, your UV filters—whether mineral or chemical—are going to behave the same way in the approved formulations. We can't guarantee that these mousse formulation sunscreens will actually work, let alone guarantee their safety."
While Friedman said it is "concerning" some brands have not followed the correct process he hopes they were "trying to provide more options to hopefully ensure everyone is using a sun protection product".
Smiling woman applying sunscreen on her face while looking in mirror in her bathroom.
Smiling woman applying sunscreen on her face while looking in mirror in her bathroom.
Ridofranz/Getty Images
When deciding how to pick out the best sunscreen, Friedman advises going with the path of least risk.
"That's going to be the sunscreens that do follow the monograph," he urged.
"I tend to also say, go with the larger brand companies, because they have the size, wherewithal and resources to actually study their products. Not just ensure they meet FDA guidelines, but they'll do clinical studies to look at tolerability, cosmesis [preservation of appearance] and even the effect of these sunscreens on other things.
"We use sunscreen not just to protect against skin cancer, but also accelerated skin aging and skin discoloration."
Friedman said finding one that's right for you is still important. "Take these tried and true brands and do patch testing to see A) does your skin tolerate it and B) does it rub in well so you're not walking around with a white or purple cast. Samples from the dermatology office are so helpful."
He recommends wearing at least an SPF 30 or higher each day.
"I tend to say 50, not because there's such a huge delta between 30 and 50—and you will never 100 percent block UV radiation—but because these numbers are based on the FDA approach to measuring efficacy," Friedman said.
While it's based on a set concentration of two milligrams of sunscreen per centimeter square of skin, most people don't put that much on.
"The higher SPFs are good because it takes into account human error," he added. "With how much people are actually applying, a 70 ends up being a 40 and a 50 ends up being 30.
"So in an ideal world: SPF, 30, maybe 50, broad spectrum, water resistant to 80 minutes. Then it's about what plays nice on your skin."
Friedman himself wears sunscreen all year round, even in winter. "Every day to exposed areas. Do you brush your teeth every day? Sunscreen is the brushing the teeth of the skin. We brush our teeth to protect the integrity and health of our teeth. Applying sunscreen is the exact same thing."
He also emphasized sunscreen is just one protection factor that should be used alongside wearing hats, sunglasses, the right clothing, seeking shade during peak hours and being fully aware. This includes knowing that windows won't block out UVA (while this will less likely cause burning, it can increase the risk of accelerated skin aging because it penetrates deeper).
Supergoop! told Newsweek: "At Supergoop! we remain committed to innovation in sun care and the highest standards of product efficacy and safety. The recent communication from the FDA regarding our PLAY SPF 50 Body Mousse is focused on product labeling and has nothing to do with its safety, effectiveness, or formula. We are working closely with the FDA to resolve this matter as we continue to uphold the high standards our consumers expect from us."
Vacation Inc told Newsweek: "At Vacation Sunscreen, we take regulatory compliance seriously and appreciate the opportunity to address the U.S. Food and Drug Administration's recent Warning Letter. We have full confidence in the safety, efficacy, and integrity of our product. We are committed to working collaboratively with the FDA to satisfactorily resolve this matter."
Kalani Sunwear told Newsweek:"Kalani Sunwear acknowledges receipt of the FDA letter and has voluntarily paused sales in the U.S. while we review the administrative requirements. Importantly, the letter relates to regulatory classification only—not to the safety or efficacy of our SPF 50 mousse. Our formula is manufactured in Sweden, independently tested to EU standards, and uses advanced UV filters that are not yet approved in the U.S. (the FDA has not approved a new UV filter since 1999). We remain fully compliant with European regulations and stand by the quality and effectiveness of our product."
Newsweek has also reached out to Botao Baby, Tizo Skin and the FDA for comment.
Do you have a tip on a health story that Newsweek should be covering? Do you have a question about sunscreen? Let us know via health@newsweek.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

"That Makes Perfect Sense": Fox News Just Got RFK Jr. To Reveal The "Convenient" Reason He Works Out In Jeans
"That Makes Perfect Sense": Fox News Just Got RFK Jr. To Reveal The "Convenient" Reason He Works Out In Jeans

Yahoo

timea few seconds ago

  • Yahoo

"That Makes Perfect Sense": Fox News Just Got RFK Jr. To Reveal The "Convenient" Reason He Works Out In Jeans

Fox News' Jesse Watters hit Health and Human Services Secretary Robert F. Kennedy Jr. with what he described as 'the question that everybody is wondering about' on Tuesday. Namely, 'Why do you wear jeans when you work out?' Related: Kennedy, known for exercising in his literal (denim) sweatpants, answered: 'Well, I just started doing that a long time ago because I would go hiking in the morning and then I'd go straight to the gym and I found it was convenient and now I'm used to it so I just do it.' Related: 'OK,' the Fox News host replied to the vaccine skeptic that President Donald Trump has entrusted with his 'Make America Healthy Again' agenda. Related: 'There were a lot of theories, but that makes perfect sense,' Watters claimed, without offering to explain the sense he claimed there was. Watch here: Fox News/X / Via Related: The question came after Kennedy and Fox News personality-turned-Defense Secretary Pete Hegseth challenged Americans to do 50 pullups and 100 pushups in under five minutes. Watch that clip here: @FoxNews/X / Via This article originally appeared on HuffPost. Also in In the News: Also in In the News: Also in In the News: Solve the daily Crossword

2.8M in US now identify as transgender: Research
2.8M in US now identify as transgender: Research

The Hill

timea minute ago

  • The Hill

2.8M in US now identify as transgender: Research

Roughly 2.8 million Americans aged 13 and older identify as transgender, accounting for approximately 1 percent of the U.S. population in that age group, according to a new estimate from the Williams Institute, a research organization focused on sexual orientation and gender identity issues. About three-quarters of people who identify as transgender in the U.S. are under 35, according to the report published Wednesday, and 25 percent are between 13 and 17. Williams Institute researchers used data from the Behavioral Risk Factor Surveillance System (BRFSS) and Youth Risk Behavior Surveillance System (YRBSS) — public health surveys administered by the Centers for Disease Control and Prevention (CDC) — and statistical modeling to estimate the population of trans adults and youth in all 50 states and Washington, D.C. About 2.1 million adults identify as transgender, accounting for approximately 0.8 percent of Americans aged 18 and older, according to Wednesday's report. Roughly 3.3 percent of 13 to 17-year-olds in the U.S., or 724,000, identify as transgender. 'Younger generations are more likely to identify as transgender, and we expect that trend to continue,' said Jody Herman, the report's lead author and a senior scholar at the Williams Institute. 'Youth and young adults are more likely to identify as transgender due to a variety of factors, including a greater willingness among younger individuals to disclose that they identify as transgender on surveys.' That finding is consistent with national surveys on LGBTQ identification. In a February Gallup poll, 23.1 percent of Gen Z said they identify as lesbian, gay, bisexual, transgender or 'something other than heterosexual,' compared with 14.2 percent of Millennials and 5.1 percent of Gen X. The Williams Institute, affiliated with the University of California, Los Angeles School of Law, has tracked the number of transgender people in the U.S. since at least 2011. In 2022, the group estimated that 1.6 million Americans identified as transgender. Most transgender people in the U.S. — about 279,000 — live in the South, according to Wednesday's report, consistent with previous years' findings. Around 175,000 transgender Americans live in the West; 156,000 in the Midwest and 114,000 in the Northeast, the Williams Institute found. Of all adults who identify as transgender, 33 percent are transgender women; 34 percent are transgender men and 33 percent are nonbinary, according to Wednesday's report. The group's estimate comes as President Trump's administration works to remove public health datasets and information from federal government websites about transgender people and identities. Affixed at the top of the CDC's webpage for the YRBSS, which the Williams Institute used in its calculation on Wednesday, is an advisory that 'Any information on this page promoting gender ideology is extremely inaccurate and disconnected from the immutable biological reality that there are two sexes, male and female.' 'The Trump Administration rejects gender ideology and condemns the harms it causes to children, by promoting their chemical and surgical mutilation, and to women, by depriving them of their dignity, safety, well-being, and opportunities,' the advisory reads. 'This page does not reflect biological reality and therefore the Administration and this Department rejects it.' Federal health agencies, including the CDC, were ordered to restore online datasets taken down after Trump issued an executive order in January prohibiting the government from promoting 'gender ideology.' Each of the restored webpages leads with notices condemning 'gender ideology.' The White House has also sought to remove questions about gender identity from national surveys on crime victimization and sexual violence. In February, former U.S. Census Bureau Director Robert Santos told NPR that the bureau had moved to strike gender identity questions from several surveys it conducts because of Trump's Jan. 20 order. 'Federal datasets that include questions about sexual orientation and gender identity have provided critical information to researchers, clinicians, policymakers, and the public,' Andrew R. Flores, a distinguished visiting scholar at the Williams Institute and one of the authors of Wednesday's report, said in a statement. 'Removal of these questions from federal surveys — such as the BRFSS and the YRBS — would significantly hinder the ability of researchers to assess the health, experiences, and needs of transgender people in the United States.'

Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval
Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval

Yahoo

time15 minutes ago

  • Yahoo

Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval

Cash truly is king. On Monday, shares in Novo Nordisk jumped 4% after the drugmaker announced that US customers who pay out-of-pocket will be able to buy its blockbuster diabetes drug Ozempic for less than half the list price. In a year of struggles against copycats, an emboldened chief rival and political pressure over high prices, executives are no doubt hoping the discount will prove a crowning achievement. READ ALSO: SoftBank Acquires a 2% Stake in Embattled Intel and Brokers Chafe Under Abrupt Expansion of Steel, Aluminum Tariffs A Letter from Washington Without insurance, Ozempic can set back US customers roughly $1,350 a month, or enough to rent a one-bedroom apartment in Kansas City (where the local barbecue might have you in need of a GLP-1 prescription). That hefty price tag has led to a bipartisan pushback in Washington, including from President Donald Trump, who sent a letter to Novo last month demanding executives lower prices for their company's treatments. Trump also urged drugmakers to develop direct-to-consumer sales models for their medicines. Americans spent $98 billion out of pocket on prescriptions last year, a 25% cumulative increase over five years, according to IQVIA, while a majority worry that prescription costs are unaffordable, according to KFF polling. Meanwhile, Novo has its own incentives to lower prices. For one, customers flocked to cheaper copycat drugs that exploded in popularity during a multi-year GLP-1 shortage, one that the FDA declared over earlier this year. And the company's chief rival in the GLP-1 space, Mounjaro- and Zepbound-maker Eli Lilly, has been binge-eating market share. Last month, the pressure prompted Novo to slash its sales and profit forecasts, prompting a massive selloff on Wall Street (shares are down 37% this year). On Monday, the company signalled it will defend its turf: Novo said cash-paying Americans can now buy Ozempic for $499 per month through its official website, its patient assistance program, its newly launched direct-to-consumer online pharmacy, or through discount telehealth platform GoodRx. The move follows Novo's decision to halve the price of weight-loss treatment Wegovy in March. Its price reductions follow similar cuts from Eli Lilly, which slashed the prices of both its weight loss and obesity GLP-1 drugs in March. David Ricks, Eli Lilly's CEO, said at the time that about 10% of the 1 million people who bought Zepbound did so from the company's website. MASHing Success: Monday's news came on the heels of a Friday victory for Novo, when Wegovy received FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH), a liver condition that affects roughly 5% of US adults, potentially opening up a market of millions of new customers. It was the first GLP-1 treatment to be approved for MASH, giving Novo a leg up against its biggest competitor. Rival Lilly, meanwhile, has run trials, inked deals and even made an acquisition earlier this year with an eye to rolling out MASH treatments. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store